Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered
- PMID: 27143006
- PMCID: PMC4853640
- DOI: 10.1192/bjp.bp.115.163261
Practising evidence-based medicine in an era of high placebo response: number needed to treat reconsidered
Abstract
The number needed to treat (NNT) statistic was developed to facilitate the practice of evidence-based medicine. Placebo was assumed to be therapeutically inert when the NNT was originally conceived, but more recent data for conditions such as major depressive disorder (MDD) suggest that the placebo control condition can have considerable therapeutic effects. Complications arise because the NNT calculated from randomised controlled trials (RCTs) reflects a comparison between medication plus clinical management and placebo plus clinical management, whereas, in the clinical setting, physicians choose between prescribing open medication, observing a patient over time with a supportive approach, and doing nothing. Thus, NNTs derived from clinical trials are not directly relevant to clinical decision-making, because they are based on control conditions that do not exist in standard practice. Additional difficulties may arise when using NNTs to compare alternative treatments for MDD, such as medication and psychotherapy, since these comparisons require the control conditions upon which the respective NNTs are based to be similar.Whereas pill placebo conditions include intensive clinical management and elicit expectations of improvement, attention control conditions for psychotherapy research are less well developed. Often the effects of psychotherapy are gauged against a wait-list control condition, which has substantially fewer therapeutic components than a pill placebo control condition. To improve the clinical utility of NNTs for the treatment of MDD, we advocate effectiveness studies that include treatment conditions resembling actual clinical practice, rather than using placebo-controlled RCTs for this purpose. Until such studies are performed, the effect of bias in comparing NNTs across treatments can be controlled by ensuring that the RCT control conditions upon which the NNTs are based are comparable.
© The Royal College of Psychiatrists 2016.
Conflict of interest statement
S.P.R. has served as a consultant to Lundbeck. B.R.R. has received honoraria from MedAvante and Pfizer and served as a consultant to RCT Logic. M.E.T. has acted as an advisor/consultant to AstraZeneca, Bristol-Myers Squibb Company, Cerecor, Inc., Eli Lilly & Company, Forest Laboratories, Johnson & Johnson (includes Ortho-McNeil Pharmaceuticals), Merck and Co. Inc., Novartis, Otsuka, Pfizer, and Shire US Inc.
Comment in
-
NNT and NNH remain helpful in evidence-based medicine.Br J Psychiatry. 2016 Sep;209(3):262-3. doi: 10.1192/bjp.209.3.262b. Br J Psychiatry. 2016. PMID: 27587765 No abstract available.
-
Authors' reply.Br J Psychiatry. 2016 Sep;209(3):263. doi: 10.1192/bjp.209.3.263. Br J Psychiatry. 2016. PMID: 27587766 No abstract available.
References
-
- Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840–7. - PubMed
-
- Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166: 42–9. - PubMed
-
- Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728–36. - PubMed
-
- Furukawa TA, Akechi T, Wagenpfeil S, Leucht S. Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Res 2011; 126: 212–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
